Largest Chinese CRO, WuXi PharmaTech, Purchases Multiyear ADMET Predictor License
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that WuXi PharmaTech (NYSE:WX), China’s largest contract research organization (CRO), has obtained a multiyear license to ADMET Predictor™, Simulations Plus’ flagship structure-to-property prediction software.
John DiBella, vice president of marketing and sales for Simulations Plus, said: “We’re very pleased that WuXi has elected to license the ADMET Predictor Toxicity Module. WuXi offers a variety of in vitro and in vivo services to assist its customers in pharmaceutical research and development. The ADMET Predictor Toxicity Module provides more than 30 different kinds of toxicity predictions, requiring only molecular structures as input. These in silico predictions will provide WuXi with an additional service offering and are expected to assist both in prioritizing which in vitro assays need to be run for particular drugs and by filling in the gaps in in vitro data in support of pre-IND (initial new drug) and IND filings with regulatory agencies for WuXi’s customers. This license is the result of the combined efforts of Simulations Plus and PharmoGo, our distributor in China.”